my personal edition > psoriasis > news
E-Mail this DGReview to a colleague
DGReview
Penile, Scrotal Cancer Still Linked To Psoralen Plus Ultraviolet-A Psoriasis Treatment
A DGReview of :"The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis"
Journal of the American Academy of Dermatology
07/23/2002
By Mark Greener
Men who undergo treatment for psoriasis with psoralen plus ultraviolet A (PUVA) are at increased risk of developing genital squamous cell carcinomas (SCCs) compared to the general population, despite measures to reduce the hazard.
Researchers from the Beth Israel Deaconess Medical Center, Boston, United Sates, performed a prospective cohort study that enrolled 892 men with psoriasis who first received PUVA between 1975 and 1976. Of these, 24 men - 2.7 percent of the total - developed 51 genital neoplasms.
Compared to the general Caucasian population, the risk that men undergoing PUVA would develop invasive penile and scrotal SCCs rose 52.6-fold. Exposure to high doses of PUVA as well as topical tar and ultraviolet B was associated with an increased incidence of genital SCCs. The increase was 4.5 fold compared with those who received low-doses.
The authors noted that the PUVA is now used less commonly and genital shielding is more widely employed than was the case several years ago. Nevertheless, men treated using PUVA still show dose-dependent increases in the risk of developing genital SCCs. In particular, men exposed to high-doses of PUVA and topical tar plus ultraviolet B are especially likely to develop genital SCCs.
J Am Acad Dermatol 2002;47:33-9.
"The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis"
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
